Escalation thresholds in the assessment of domino accidental events.

J Hazard Mater

Dipartimento di Ingegneria Chimica, Mineraria e delle Tecnologie Ambientali, Università degli Studi di Bologna, viale Risorgimento n.2, 40136 Bologna, Italy.

Published: February 2006

Domino effect is responsible of several catastrophic accidents that took place in the chemical and process industry. Although the destructive potential of these accidental scenarios is widely recognized, scarce attention was paid to this subject in the scientific and technical literature. Thus, well-assessed procedures for the quantitative evaluation of risk caused by domino effect are still lacking. Moreover, a wide uncertainty is present with respect to escalation criteria, and even in the identification of the escalation sequences that should be taken into account in the analysis of domino scenarios, either in the framework of quantitative risk analysis or of land-use planning. The present study focused on the revision and on the improvement of criteria for escalation credibility, based on recent advances in the modelling of fire and explosion damage to process equipment due to different escalation vectors (heat radiation, overpressure and fragment projection). Revised threshold values were proposed, and specific escalation criteria were obtained for the primary scenarios more frequently considered in the risk assessment of industrial sites.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhazmat.2005.08.012DOI Listing

Publication Analysis

Top Keywords

escalation criteria
8
escalation
6
escalation thresholds
4
thresholds assessment
4
domino
4
assessment domino
4
domino accidental
4
accidental events
4
events domino
4
domino responsible
4

Similar Publications

Objective: We demonstrated for the first time the safety and feasibility of escalating up to 55 Gy/11 Gy/fr/5fr in borderline (BRPC)/unresectable locally advanced pancreatic cancer (LAPC), using the standard LINAC platform. The aim of the present study is to assess for the first time the impact of this high-dose neoadjuvant stereotactic ablative radiotherapy (SABRT) protocol on tumor resectability and pathological responses.

Materials/methods: From June 2017 to December 2022, patients with BRPC/LAPC were treated with neoadjuvant chemotherapy (ChT) and SABRT-escalated doses of SIB at 45 Gy, 50 Gy, and up to 55 Gy (BED ≥ 100).

View Article and Find Full Text PDF

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil.

Biomedicines

January 2025

Chair and Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, ERN-LUNG Member, 05-400 Otwock, Poland.

: Treprostinil, which is administered via continuous subcutaneous or intravenous infusion, is a medication applied in the treatment of pulmonary arterial hypertension (PAH). The dose of treprostinil is adjusted on an individual basis for each patient. A number of factors determine how well patients respond to treatment.

View Article and Find Full Text PDF

Background: The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. The efficacy of radiotherapy (RT) for chest consolidation has been established for patients with ED-SCLC who have responded to chemotherapy. There is a lack of data on incorporating RT as chest consolidation and metastasis-directed therapy for ED-SCLC.

View Article and Find Full Text PDF

Background: Preclinical studies and anecdotal case reports support the potential therapeutic benefit of low-dose oral ketamine as a treatment of clinical symptoms in Rett syndrome (RTT); however, no controlled studies have been conducted in RTT to evaluate safety, tolerability and efficacy.

Design: This was a sequentially initiated, dose-escalating cohort, placebo-controlled, double blind, randomized sequence, cross-over study of oral ketamine in 6-12-year-old girls with RTT to evaluate short-term safety and tolerability and explore efficacy.

Methods: Participants were randomized to either five days treatment with oral ketamine or matched placebo, followed by a nine-day wash-out period and then crossed-over to the opposite treatment.

View Article and Find Full Text PDF

Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.

Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!